12/9/2013 10:14:23 AM
BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the launch of a new oncology panel on its next generation sequencing (NGS) platform. The IntelliGEN assay improves sensitivity and detection rates for somatic mutations in cancer, assessing approximately 2600 mutations within 50 oncogenes/tumor suppressor genes. IntelliGEN will be available through Integrated Oncology, a member of the LabCorp Specialty Testing Group.
Help employers find you! Check out all the jobs and post your resume.
comments powered by